4.7 Article

DDC-Promoter-Driven Chemogenetic Activation of SNpc Dopaminergic Neurons Alleviates Parkinsonian Motor Symptoms

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Review Biochemistry & Molecular Biology

Revisiting the Role of Astrocytic MAOB in Parkinson's Disease

Min-Ho Nam et al.

Summary: This study shows that in Parkinson's disease, MAOB is involved in the aberrant synthesis of GABA and H2O2 in reactive astrocytes, leading to gradual damage and death of dopaminergic neurons.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Review Biochemistry & Molecular Biology

Gene-Based Therapeutics for Parkinson's Disease

Karim E. Shalaby et al.

Summary: Gene therapy has the potential to replace current treatments for Parkinson's disease and has been shown to be safe and effective in current trials.

BIOMEDICINES (2022)

Article Neurosciences

Restoring lost nigrostriatal fibers in Parkinson's disease based on clinically-inspired design criteria

Wisberty J. Gordian-Velez et al.

Summary: Parkinson's disease is a global neurodegenerative disease affecting approximately 10 million people worldwide, characterized by the death of dopaminergic neurons and axonal fibers leading to dopamine loss in the striatum and motor symptoms. Current treatments focus on symptom reduction, with pathway reconstruction emerging as an alternative approach involving implanting tissue-engineered nigrostriatal pathways into the brain. This method aims to restore proper dopamine release and motor circuit regulation.

BRAIN RESEARCH BULLETIN (2021)

Article Multidisciplinary Sciences

Optogenetic stimulation of glutamatergic neurons in the cuneiform nucleus controls locomotion in a mouse model of Parkinson's disease

Maxime Fougere et al.

Summary: In a mouse model of PD, selective optogenetic stimulation of glutamatergic neurons in the cuneiform nucleus increased the number of locomotor initiations, extended the time spent in locomotion, and controlled locomotor speed. This suggests that glutamatergic neurons in the cuneiform nucleus may be a potential clinically relevant target to improve locomotor activity in parkinsonian conditions.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)

Article Medicine, Research & Experimental

The Pathological Role of Astrocytic MAOB in Parkinsonism Revealed by Genetic Ablation and Over-expression of MAOB

Heeyoung An et al.

Summary: Traditionally, the cause of Parkinson's disease is believed to be the death of dopaminergic neurons, but recent research suggests that aberrant GABA release from reactive astrocytes also plays a significant role in the pathological process. The study demonstrates the essential role of MAOB in Parkinsonian motor symptoms, with genetic ablation blocking the augmentation of astrocytic GABA-mediated tonic inhibition and parkinsonian symptoms. Conversely, over-expression of MAOB in astrocytes exacerbates parkinsonian motor symptoms, providing genetic evidence for the link between astrocytic MAOB-dependent tonic GABA synthesis and Parkinsonian motor symptoms.

EXPERIMENTAL NEUROBIOLOGY (2021)

Article Clinical Neurology

KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson's Disease

Min-Ho Nam et al.

Summary: KDS2010, a recently synthesized potent, selective, and reversible MAO-B inhibitor, showed potential therapeutic effects for Parkinson's disease (PD), demonstrating significant neuroprotective and anti-neuroinflammatory efficacy in animal models and alleviating motor dysfunction in PD rat models.

NEUROTHERAPEUTICS (2021)

Letter Biotechnology & Applied Microbiology

AAV Vectors: Are They Safe?

Arun Srivastava

HUMAN GENE THERAPY (2020)

Review Pharmacology & Pharmacy

Gene Therapy Tools for Brain Diseases

Selene Ingusci et al.

FRONTIERS IN PHARMACOLOGY (2019)

Article Biochemistry & Molecular Biology

Behavioral tests predicting striatal dopamine level in a rat hemi-Parkinson's disease model

Kazuya Miyanishi et al.

NEUROCHEMISTRY INTERNATIONAL (2019)

Article Medicine, Research & Experimental

Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy

Cristina Alcacer et al.

JOURNAL OF CLINICAL INVESTIGATION (2017)

Review Neurosciences

DREADDs for Neuroscientists

Bryan L. Roth

NEURON (2016)

Article Medicine, Research & Experimental

Neurotoxin-Induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling

Senthil Selvaraj et al.

JOURNAL OF CLINICAL INVESTIGATION (2012)

Article Biochemistry & Molecular Biology

Neuronal activity regulates expression of tyrosine hydroxylase in adult mouse substantia nigra pars compacta neurons

Tim D. Aumann et al.

JOURNAL OF NEUROCHEMISTRY (2011)

Article Cell Biology

α-Synuclein impairs macroautophagy: implications for Parkinson's disease

Ashley R. Winslow et al.

JOURNAL OF CELL BIOLOGY (2010)

Article Multidisciplinary Sciences

Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1

Jaime N. Guzman et al.

NATURE (2010)

Article Multidisciplinary Sciences

Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry

Alexxai V. Kravitz et al.

NATURE (2010)

Editorial Material Virology

Novel Viral Vector Systems for Gene Therapy

Daniel Stone

VIRUSES-BASEL (2010)

Article Biochemistry & Molecular Biology

Activation of the unfolded protein response in Parkinson's disease

J. J. M. Hoozemans et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)

Review Medicine, General & Internal

Parkinson's disease

A Samii et al.

LANCET (2004)